Table 3.
HIV-specific treatment characteristics by cervical cancer stage at diagnosis among HIV-positive patients, Kampala, Uganda, 2013–2015.
| Characteristic | Early stage, % (#) (n = 36) |
Late stage, % (#) (n = 17) |
|---|---|---|
| Duration of HIV infection | ||
| - <1 year | 6 (17) | 2 (12) |
| − 1–5 years | 10 (29) | 7 (44) |
| - >5 years | 19 (54) | 7 (44) |
| - Unknown* | 1 | 1 |
| CD4 T-cell count at enrollment | ||
| - >500 cells/mm3 | 9 (25) | 5 (29) |
| − 201–500 cells/mm3 | 24 (67) | 8 (47) |
| − 0–200 cells/mm3 | 3 (8) | 4 (24) |
| HIV plasma RNA level at enrollment | ||
| - <500 copies/mL | 27 (75) | 14 (82) |
| - ≥500 copies/mL | 9 (25) | 3 (18) |
| HAART use at enrollment | ||
| - No | 8 (22) | 4 (24) |
| - Yes | 28 (78) | 13 (76) |
| Enrolled in HIV care services at enrollment | ||
| - No | 3 (9) | 3 (18) |
| - Yes | 31 (91) | 14 (82) |
| - Unknown* | 2 | 0 |
*
Missing data are shown as separate category for categorical variables, but percentages were calculated among non-missing data only.